Fresenius Medical Care AG & Co. KGaA Sponsored ADR Aktie News

Fresenius Medical Care delivers on commitments during a year of fundamental transformation Progress towards sustainability goals in key areas: patient satisfaction, diversity in management, climate target roadmap BAD HOMBURG, Germany , March 22, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, today pub...

For the first time, Fresenius Medical Care develops and utilizes "Augmented Reality" (AR) to train medical staff in Intensive Care Units (ICUs) The new training application for ICU staff combines digital learning elements with real-life training on the Fresenius Medical Care Continuous Kidney Replacement Therapy system This learning experience reinforces initial training, a supplement to suppor...

Effective June 1, the Legal, Compliance, and Human Resources functions will be combined in a new Management Board role Jörg Häring contributes his extensive expertise from the energy, industry, and healthcare sectors BAD HOMBURG, Germany , March 13, 2024 /PRNewswire/ -- Fresenius Medical Care, the world's leading provider of products and services for individuals with renal diseases, has announc...

Divestment of assets includes four separate country transactions to DaVita Inc. for USD 300 million Transactions further reduce the Company`s clinic footprint in Latin America, following the exit from Argentina at the end of 2023 Expected to close throughout 2024 Proceeds to be used to reduce debt BAD HOMBURG, Germany , March 5, 2024 /PRNewswire/ -- Fresenius Medical Care, the world's leading p...

Fresenius Medical Care AG (FMS) Q4 2023 Earnings Call Transcript

Revenue growth of 5% in 2023 driven by favorable business development Operating income1 growth of 15% exceeding top end of outlook range, due to business growth, FME25 savings ahead of plan and contributions from the Tricare settlement Successful execution on turnaround plan resulting in significant labor productivity improvements in Care Delivery and positive pricing in Care Enablement Several...

Fresenius Medical Care (FME) receives U.S. Food and Drug Administration (FDA) 510(k) clearance of the company's 5008X Hemodialysis System. This will enable Fresenius Medical Care to offer the industry-leading, high-volume hemodiafiltration (Hv-HDF) dialysis therapy – already widely used in Europe – for people living with kidney diseases in the U.S. The 510(k) clearance allows the start of clini...

BAD HOMBURG, Germany , Feb. 5, 2024 /PRNewswire/ -- Fresenius Medical Care (FME), the world's leading provider of products and services for individuals with renal diseases, has nominated six employee representatives as members of the company's Supervisory Board. Effective January 26, the competent court approved the company's application for the judicial appointment of the six employee represen...